Zaxone TBZ injection

/Zaxone TBZ injection
Zaxone TBZ injection 2018-07-13T04:06:26+00:00

Zaxone TBZ contains ceftriaxone and tazobactum.

Ceftriaxone is an antibiotic which is used for the treatment of bacterial infections. It is a broad spectrum antibiotic which is active against gram positive bacteria

and also active for gram negative.  Tazobactum is a pharmaceutical ingredient which is produces its action by inhibition of beta-lactamases.

  • Lower respiratory tract infections

  • Community acquired pneumonia

  • Acute bacterial otitis media

  • Urinary tract infections

  • Skin and skin structure infections

  • Pelvic inflammatory disease

  • Bacterial septicemia

  • Bone and joint infection

  • Intra-abdominal infections

  • Peri-operative prophylaxsis of infections associated with surgery

  • Bacterial meningitis

  • Intra-abdominal infections

50-75 mg/kg in every 12hrs or total dose should not exceed 2gm.

Ceftriaxone produces its action interfering with the biosynthesis of peptidoglycon which is required for bacterial cell. It also inactivates penicillin binding proteins.

Tazobactum is having beta lactamase inhibitory properties and have a penicillinic acid derivative sulphone derivative. It is active against beta-lactamase producing bacteria.


The drug is effective against all organisms sensitive to ceftriaxone. Both the drug produces synergistic effect in combination.


Ceftriaxone is about 98% bound to plasma proteins. It is also able to pass through blood brain barrier. 30% of the tazobactum is bound to plasma protein and the drug is widely distributed in body.


The elimination half life of ceftrixone is about 8.7hrs. About 37-67% of the drug is removed in unchanged form.

  • Hypersensitivity to cephalosporins and beta-lactamase

  • Hyperbilirubinemic neonates, especially prematures

  • Penicillin allergy

  • Pseudomembranous colitis in patient with diarrhea

  • Analysis of prothrombin time in patients with impaired vitamin K synthesis

  • Prolong treatment causes overgrowth

  • Hyperbiolirubinemic neonates, mainly in prematures

  • Patient with history of GI diseases

WhatsApp chat